Ovid Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| (in thousands, except share and per share data) | For the Year Ended December 31, 2024 | For the Year Ended December 31, 2023 |
|---|---|---|
| Revenue: | ||
| License and other revenue | $566 | $392 |
| Total revenue | 566 | 392 |
| Operating expenses: | ||
| Research and development | 36,767 | 28,588 |
| General and administrative | 25,684 | 31,085 |
| Total operating expenses | 62,451 | 59,673 |
| Loss from operations | (61,885) | (59,281) |
| Other income (expense), net | 35,452 | 6,943 |
| Loss before provision for income taxes | (26,433) | (52,339) |
| Provision for income taxes | — | — |
| Net loss | $(26,433) | $(52,339) |
| Net loss per share of Series A preferred stock, basic and diluted | $(366.33) | $(728.64) |
| Weighted-average Series A preferred stock shares outstanding, basic and diluted | 1,250 | 1,250 |
| Net loss per share of common stock, basic and diluted | $(0.37) | $(0.73) |
| Weighted-average common stock shares outstanding, basic and diluted | 70,905,422 | 70,580,604 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.